Study To Determine The Pharmacokinetics Of Sulfasalazine In Children With Juvenile Idiopathic Arthritis

This study is currently recruiting participants.

Verified by Pfizer, April 2009

First Received: March 11, 2008 Last Updated: April 15, 2009 History of Changes

Sponsored by:	Pfizer
Information provided by:	Pfizer
ClinicalTrials.gov Identifier:	NCT00637780

Purpose

This study will characterize the steady state pharmacokinetics of sulfasalazine delayed release tablets in pediatric Juvenile Idiopathic Arthritis patients. Data from this study will fulfill the post approval commitment to the FDA.

Condition	Intervention	Phase
Arthritis, Juvenile Rheumatoid	Drug: Sulfasalazine	Phase I

MedlinePlus related topics: Juvenile Rheumatoid Arthritis

Drug Information available for: Sulfasalazine

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Parallel Assignment, Pharmacokinetics Study
Official Title:	An Open Label Non-Randomized Study To Characterize The Steady State Pharmacokinetics Of Sulfasalazine Delayed Release Tablets In Children With Juvenile Idiopathic Arthritis

Further study details as provided by Pfizer:

Primary Outcome Measures:

Pharmacokinetic endpoints to include:sulfasalazine, sulfapyridine and 5-aminosalicylic acid: steady state (Day 7): Cmax ss, Tmax ss, AUCtau , Cmin ss, t1/2(data permitting) [ Time Frame: Day 7 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Safety endpoints to include adverse events, safety laboratory tests, and vital signs. [ Time Frame: Day 1 through Day 9 ] [ Designated as safety issue: No ]

Estimated Enrollment:	12
Study Start Date:	March 2009
Estimated Study Completion Date:	May 2009
Estimated Primary Completion Date:	May 2009 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
1: Experimental Sulfasalazine delayed release tablets 30-60 mg/kg/day (divided into BID doses) for 6 days	Drug: Sulfasalazine Sulfasalazine delayed release tablets 30-60 mg/kg/day (divided into BID doses) for 7 days. Blood sampling for Pharmacokinetic assessment to be performed on Day 7

Eligibility

Ages Eligible for Study:	6 Years to 17 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patients with a diagnosis of oligoarticular, polyarticular, psoriatic or enthesitis-related JIA as determined by ILAR criteria.

Patients with a history of systemic onset JIA whose disease has progressed to polyarthritis or oligoarthritis without current systemic features and who have been continuously treated with sulfasalazine (Azulfidine-EN) and have tolerated the product for at least 3 months prior to study enrolment are eligible.

Patients must be at least 6 years of age and has not reached his/her 18th birthday prior to the Baseline Visit (Day 0).
Onset of JIA must have occurred prior to the patient's 16th birthday.
Patients must weigh at least 16 kg.
Patients must be on sulfasalazine 500 mg delayed release tablets and the total daily dose must be within the specified range of 30-60 mg/kg/day with a maximum daily dose of 3 g/day

Exclusion Criteria:

Patient with a history of or currently in the active phase of systemic JIA.
Hypersensitivity to sulfasalazine , its metabolites, sulfonamides or salicylates.
History of sensitivity to heparin or heparin-induced thrombocytopenia.
Inability to swallow whole (uncrushed) sulfasalazine 500 mg delayed release tablets as required by protocol

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00637780

Contacts

Contact: Pfizer CT.gov Call Center

1-800-718-1021

Locations

United States, New York
Pfizer Investigational Site	Recruiting
New York, New York, United States, 10032

Sponsors and Collaborators

Pfizer

Investigators

Study Director:

Pfizer CT.gov Call Center

Pfizer

More Information

Additional Information:

To obtain contact information for a study center near you, click here. This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party:	Pfizer ( Director, Clinical Trial Disclosure Group )
Study ID Numbers:	A0031005
Study First Received:	March 11, 2008
Last Updated:	April 15, 2009
ClinicalTrials.gov Identifier:	NCT00637780 History of Changes
Health Authority:	United States: Food and Drug Administration

Keywords provided by Pfizer:

Sulfasalazine delayed release tablets, azulfidine entabs, Pharmacokinetics, Juvenile Idiopathic Arthritis (JIA)

Study placed in the following topic categories:

Anti-Inflammatory Agents
Arthritis, Juvenile Rheumatoid
Autoimmune Diseases
Joint Diseases
Sulfasalazine
Arthritis, Rheumatoid
Rheumatic Diseases
Musculoskeletal Diseases

Analgesics, Non-Narcotic
Arthritis
Connective Tissue Diseases
Anti-Inflammatory Agents, Non-Steroidal
Peripheral Nervous System Agents
Analgesics
Antirheumatic Agents

Additional relevant MeSH terms:

Anti-Inflammatory Agents
Anti-Infective Agents
Arthritis, Juvenile Rheumatoid
Autoimmune Diseases
Immune System Diseases
Joint Diseases
Sulfasalazine
Physiological Effects of Drugs
Gastrointestinal Agents
Arthritis, Rheumatoid
Rheumatic Diseases
Pharmacologic Actions

Musculoskeletal Diseases
Sensory System Agents
Analgesics, Non-Narcotic
Therapeutic Uses
Arthritis
Connective Tissue Diseases
Anti-Inflammatory Agents, Non-Steroidal
Peripheral Nervous System Agents
Analgesics
Antirheumatic Agents
Central Nervous System Agents

ClinicalTrials.gov processed this record on May 07, 2009